TherapeuticsMD (TXMD) Misses Q2 EPS by 1c

TherapeuticsMD (NYSE: TXMD) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.63 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• General Mills (GIS) PT Lowered to $42 at Freedom Broker
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform